Literature DB >> 25729480

Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance.

Angelica Maldonado-Rodriguez1, Ana Maria Cevallos1, Othon Rojas-Montes1, Karina Enriquez-Navarro1, Ma Teresa Alvarez-Muñoz1, Rosalia Lira1.   

Abstract

The prevalence of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infection is high as they share similar mechanisms of transmission. The development and widespread use of highly sensitive tests for HBV diagnosis has demonstrated that a significant proportion of apparently healthy individuals with evidence of exposure to HBV continue to carry fully functional HBV DNA in their hepatocytes, a situation that predisposes them to the development of progressive liver disease and hepatocellular carcinoma. The presence of co-infections frequently influences the natural evolution of each of the participating infections present by either facilitating their virulence or competing for resources. Furthermore, the drugs used to treat these infections may also contribute to changes in the natural course of these infections, making the analysis of the impact of co-infection more difficult. The majority of studies has examined the impact of HIV on overt chronic hepatitis B, finding that co-infection carries an increased risk of progressive liver disease and the development of hepatocellular carcinoma. Although the effect of HIV on the natural history of occult hepatitis B infection (OBI) has not been fully assessed, all available data suggest a persisting risk of repeated flares of hepatitis and progressive liver disease. We describe studies regarding the diagnosis, prevalence and clinical significance of OBI in HIV-positive patients in this short review. Discrepancies in worldwide prevalence show the urgent need for the standardization of diagnostic criteria, as established by the Taormina statements. Ideally, standardized protocols for testing should be employed to enable the comparison of data from different groups. Additional studies are needed to define the differences in risk for OBI without HIV and in HIV-HBV co-infected patients with or without overt disease.

Entities:  

Keywords:  Clinical significance; Diagnosis; Hepatitis B virus; Human immunodeficiency virus; Occult hepatitis B; Prevalence

Year:  2015        PMID: 25729480      PMCID: PMC4342607          DOI: 10.4254/wjh.v7.i2.253

Source DB:  PubMed          Journal:  World J Hepatol


  63 in total

1.  Immunogenicity and safety of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) in South African children.

Authors:  M J Mphahlele; R J Burnett; T Kyaw; H S Schoeman; S Aspinall
Journal:  S Afr Med J       Date:  2004-04

Review 2.  Occult hepatitis B virus infection.

Authors:  Giovanni Raimondo; Teresa Pollicino; Irene Cacciola; Giovanni Squadrito
Journal:  J Hepatol       Date:  2006-11-07       Impact factor: 25.083

3.  Occult hepatitis B virus infection: bit player or role player?

Authors:  Abdirashid M Shire; Lewis R Roberts
Journal:  Hepatology       Date:  2011-09-02       Impact factor: 17.425

Review 4.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Authors:  R P Perrillo
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

5.  Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations.

Authors:  Michel V F Sucupira; Francisco C A Mello; Eneida A Santos; Christian Niel; Valeria C Rolla; Juçara Arabe; Selma A Gomes
Journal:  Mem Inst Oswaldo Cruz       Date:  2006-09       Impact factor: 2.743

6.  Distribution of total DNA and cccDNA in serum and PBMCs may reflect the HBV immune status in HBsAg+ and HBsAg- patients coinfected or not with HIV or HCV.

Authors:  V Loustaud-Ratti; A Wagner; P Carrier; V Marczuk; I Chemin; F Lunel; I Fouchard-Hubert; S Si Ahmed; A Abergel; A Rousseau; A Lefebvre; M Debette-Gratien; F Denis; S Alain
Journal:  Clin Res Hepatol Gastroenterol       Date:  2013-03-09       Impact factor: 2.947

7.  Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients.

Authors:  Koffi Alain Attia; Serge Eholié; Eugène Messou; Christine Danel; Sandrine Polneau; Henri Chenal; Thomas Toni; Myreille Mbamy; Catherine Seyler; Naomi Wakasugi; Thérèse N'dri-Yoman; Xavier Anglaret
Journal:  World J Hepatol       Date:  2012-07-27

8.  Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: a point prevalence study.

Authors:  D Chadwick; T Doyle; S Ellis; D Price; I Abbas; M Valappil; A M Geretti
Journal:  HIV Med       Date:  2013-10-03       Impact factor: 3.180

9.  Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt--that is the question.

Authors:  Trevor G Bell; Euphodia Makondo; Neil A Martinson; Anna Kramvis
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

Review 10.  Medical virology of hepatitis B: how it began and where we are now.

Authors:  Wolfram H Gerlich
Journal:  Virol J       Date:  2013-07-20       Impact factor: 4.099

View more
  8 in total

1.  Prevalence of Overt and Occult Hepatitis B Virus Infection among HIV-Positive People Referring to Consultation Center for Behavioral Diseases, Kurdistan Province, Iran

Authors:  Fuad Azmoudeh-Ardalan; Mazaher Khodabandehloo
Journal:  Iran Biomed J       Date:  2021-11-01

2.  Molecular characterization of hepatitis B virus X gene in HIV-positive South Africans.

Authors:  Maemu P Gededzha; Tsakani H Sondlane; Lesibana A Malinga; Rosemary J Burnett; Ramokone L Lebelo; Jason T Blackard; M Jeffrey Mphahlele; Selokela G Selabe
Journal:  Virus Genes       Date:  2018-02-06       Impact factor: 2.332

3.  High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana.

Authors:  Kathleen Ryan; Motswedi Anderson; Ivayla Gyurova; Lilliam Ambroggio; Sikhulile Moyo; Teresa Sebunya; Joseph Makhema; Richard Marlink; Max Essex; Rosemary Musonda; Simani Gaseitsiwe; Jason T Blackard
Journal:  Open Forum Infect Dis       Date:  2017-09-13       Impact factor: 3.835

4.  Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India.

Authors:  Debraj Saha; Ananya Pal; Neelakshi Sarkar; Dipanwita Das; Jason T Blackard; Subhasish Kamal Guha; Bibhuti Saha; Runu Chakravarty
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

5.  Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers.

Authors:  Vincenzo Malagnino; Carlotta Cerva; Elisabetta Teti; Laura Campogiani; Mirko Compagno; Luca Foroghi Biland; Laura Saderi; Daniele Armenia; Romina Salpini; Valentina Svicher; Giovanni Sotgiu; Marco Iannetta; Massimo Andreoni; Loredana Sarmati
Journal:  Sci Rep       Date:  2021-02-17       Impact factor: 4.379

6.  Molecular investigation of occult hepatitis B virus infection in a reference center in Northern Brazil.

Authors:  Suellen Dos Reis Araújo; Andreza Pinheiro Malheiros; Vânia Pinto Sarmento; Heloisa Marceliano Nunes; Pedro Eduardo Bonfim Freitas
Journal:  Braz J Infect Dis       Date:  2022-05-20       Impact factor: 3.257

7.  High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany.

Authors:  Klaus Jansen; Michael Thamm; Claus-Thomas Bock; Ramona Scheufele; Claudia Kücherer; Dieter Muenstermann; Hans-Jochen Hagedorn; Heiko Jessen; Stephan Dupke; Osamah Hamouda; Barbara Gunsenheimer-Bartmeyer; Karolin Meixenberger
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

8.  Detection of occult hepatitis B in serum and oral fluid samples.

Authors:  Moyra Machado Portilho; Leticia Cancella Nabuco; Cristiane Alves Villela-Nogueira; Carlos Eduardo Brandão-Mello; José Henrique Pilotto; Geane Lopes Flores; Lia Laura Lewis-Ximenez; Elisabeth Lampe; Livia Melo Villar
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-01       Impact factor: 2.743

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.